Mirtazapina Bluepharma (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors while enhancing 5‑HT1 activity. This combined effect improves serotonergic and noradrenergic neurotransmission, contributing to its antidepressant action.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) which primarily increase serotonin levels. Its combined noradrenergic and specific serotonergic activity often results in a distinct side‑effect profile, including sedation and weight gain, which may be advantageous or disadvantageous compared with SSRIs depending on patient needs.

Mirtazapina Bluepharma should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, light, and excessive heat to maintain stability.

The medication is taken orally, usually once daily in the evening, as directed by a healthcare provider. It should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks include severe neutropenia, hypersensitivity reactions such as rash or anaphylaxis, and the possible emergence or worsening of suicidal thoughts, especially during early treatment or dose changes. Prompt medical attention is required if any of these occur.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate manic episodes.